2013
Immune gene expression in primary melanomas to predict lower risk of recurrence and death.
Sivendran S, Chang R, Harcharik S, Hall L, Bernardo S, Moskalenko M, Phelps R, Sivendran M, Cohain A, DiFeo A, Parides M, Lebwohl M, Friedlander P, Banchereau J, Bhardwaj N, Oh W, Burakoff S, Palucka K, Merad M, Saenger Y. Immune gene expression in primary melanomas to predict lower risk of recurrence and death. Journal Of Clinical Oncology 2013, 31: 3014-3014. DOI: 10.1200/jco.2013.31.15_suppl.3014.Peer-Reviewed Original ResearchPrediction of non-recurrenceIndependent patient cohortReceiver Operating CharacteristicProlonged survivalMRNA copy numberNon-recurrenceTraining cohortPatient cohortGene panelLow risk of recurrencePrimary human melanomaStandard prognostic indicatorsImmune-related genesRisk of recurrenceReceiver operating characteristic curvePrimary melanomaImmunotherapy studiesMelanoma recurrencePrognostic indicatorImmune biomarkersRecurrence riskMitotic rateHuman melanomaPrevent recurrencePatient stratification
1995
Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor
Seidman A, Portenoy R, Yao T, Lepore J, Mont E, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M, Usakewicz J, Southrada M, Houston C, McCabe M, Salvaggio R, Thaler H, Norton L. Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor. Journal Of The National Cancer Institute 1995, 87: 1316-1322. PMID: 7544834, DOI: 10.1093/jnci/87.17.1316.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerQuality of lifePhase II clinical trialStandard prognostic factorsGranulocyte colony-stimulating factorTumor responseBreast cancerColony-stimulating factorPrognostic factorsLife scoresSerial assessmentClinical trialsLife instrumentsGrade 4 nonhematologic toxicityLife assessmentRecombinant human granulocyte colony-stimulating factorStandard prognostic indicatorsAdvanced breast cancerPhase II trialExtent of diseaseMajority of patientsPartial tumor responseExtensive prior chemotherapyHuman granulocyte colony-stimulating factorBase-line scores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply